What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a biotech executive?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We speak with our colleagues Jason Mast and Matthew Herper about their impactful look at one father’s mission to develop a treatment for his daughter’s ultra-rare disease. The subject of that feature, Matt Wilsey, also joins us.

We also discuss STAT’s investigation into the GLP-1 prescribing practices of telehealth company LifeMD, as well as other news in the life sciences, including a legal battle between Novo Nordisk and Eli Lilly and the latest revelations on a most-wanted fugitive.

To read the feature on Wilsey, go here; for more on the investigation into the telehealth company, go here; to learn more about the fugitive, go here; and for more on Novo and Lilly’s legal battle, go here.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.